Literature DB >> 17846139

Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.

Christopher M Rubino1, Lei Ma, Sujata M Bhavnani, Joan Korth-Bradley, John Speth, Evelyn Ellis-Grosse, Keith R Rodvold, Paul G Ambrose, George L Drusano.   

Abstract

The objective of these analyses was to assess the penetration of tigecycline into colon wall tissue and epithelial lining fluid (ELF). The analyses included data from subjects without infection (phase 1) and patients with intra-abdominal infections (phase 2/3). Steady-state serum samples were collected from all subjects/patients (n = 577), while colon wall specimens (n = 23) and ELF specimens (n = 30) were obtained from subjects without infection. Tissue and serum data were simultaneously comodeled by using the BigNPAG program, and a four-compartment, open model with zero-order intravenous input and first-order elimination was employed. To examine the full range of tissue penetration and the associated probabilities of occurrence, a 9,999-subject Monte Carlo simulation was performed with two outputs, one for ELF penetration and one for colon wall tissue penetration. Data were well fit using models described above, with all r(2) values above 0.95. For subjects without infection, the median (5th and 95th percentiles) colon wall and ELF penetration ratios were 1.73 (0.160 and 199) and 1.15 (0.561 and 5.23), respectively. Simulation results predict that tissue penetration varies considerably and likely explain unexpected clinical outcomes for those patients infected with strains at margins of the MIC distribution.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846139      PMCID: PMC2151455          DOI: 10.1128/AAC.00065-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation.

Authors:  G L Drusano; S L Preston; M H Gotfried; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.

Authors:  Paul G Ambrose; Jack B Anon; Joel S Owen; Scott Van Wart; Mary Eileen McPhee; Sujata M Bhavnani; Marion Piedmonte; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2004-05-12       Impact factor: 9.079

3.  Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.

Authors:  Gopal Muralidharan; Marlynne Micalizzi; John Speth; Donald Raible; Steven Troy
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Microlavage: a technique for determining the volume of epithelial lining fluid.

Authors:  D R Baldwin; R Wise; J M Andrews; D Honeybourne
Journal:  Thorax       Date:  1991-09       Impact factor: 9.139

5.  Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.

Authors:  Keith A Rodvold; Mark H Gotfried; Michael Cwik; Joan M Korth-Bradley; Gary Dukart; Evelyn J Ellis-Grosse
Journal:  J Antimicrob Chemother       Date:  2006-09-29       Impact factor: 5.790

6.  Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.

Authors:  John E Conte; Jeffrey A Golden; Mary Grace Kelly; Elisabeth Zurlinden
Journal:  Int J Antimicrob Agents       Date:  2005-06       Impact factor: 5.283

Review 7.  Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.

Authors:  J Rello
Journal:  J Chemother       Date:  2005-08       Impact factor: 1.714

8.  A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin.

Authors:  G L Drusano; S L Preston; M Van Guilder; D North; M Gombert; M Oefelein; L Boccumini; B Weisinger; M Corrado; J Kahn
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

9.  Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.

Authors:  C Lamer; V de Beco; P Soler; S Calvat; J Y Fagon; M C Dombret; R Farinotti; J Chastre; C Gibert
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

10.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

View more
  13 in total

Review 1.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

2.  In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.

Authors:  Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 3.  Nonlinear Protein Binding: Not What You Think.

Authors:  Amelia N Deitchman; Ravi Shankar Prasad Singh; Hartmut Derendorf
Journal:  J Pharm Sci       Date:  2018-04-04       Impact factor: 3.534

4.  Clostridioides difficile-Associated Antibiotics Alter Human Mucosal Barrier Functions by Microbiome-Independent Mechanisms.

Authors:  Jemila C Kester; Douglas K Brubaker; Jason Velazquez; Charles Wright; Douglas A Lauffenburger; Linda G Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 5.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

6.  Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women.

Authors:  Kevin P Connors; Seth T Housman; J Samuel Pope; John Russomanno; Edward Salerno; Eric Shore; Susan Redican; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

7.  Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.

Authors:  Brianna Kispal; Sandra A N Walker
Journal:  Eur J Clin Pharmacol       Date:  2020-09-25       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics and pharmacodynamics of tigecycline.

Authors:  April Barbour; Stephan Schmidt; Benjamin Ma; Lars Schiefelbein; Kenneth H Rand; Olaf Burkhardt; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.

Authors:  S M Bhavnani; C M Rubino; P G Ambrose; T J Babinchak; J M Korth-Bradley; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

10.  Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin.

Authors:  K S Estes; Hartmut Derendorf
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.